EGFR and glioma: In contrast, there was no statistically significant difference in T cell activation (%CD3+/GrzB+) between Erbitux-CAR, EGFR806-CAR, and CD19-CAR T cells that infiltrated the CD19+EGFR+ U87 glial tumor mass (Figure 6D).